Spring Bank Pharmaceuticals, Inc. announced that Dr. Thomas Hayman, MD, Ph.D., a resident in the Department of Therapeutic Radiology at Yale Cancer Center, will present at the 2019 ASTRO Annual Meeting. Dr. Hayman will discuss the results from the study of activating the STimulator of INterferon Genes (STING) pathway using SB 11285, Spring Bank’s intravenously (IV)-administered STING agonist development compound, in combination with radiation therapy. The results demonstrated that the addition of IV SB 11285 to radiation therapy enhanced effectiveness in killing tumors vs. radiation alone in pre-clinical models. The addition of IV SB 11285 showed a synergistic effect in shrinking tumors when combined with radiation in xenograft models of head and neck tumors in mice. Previous data have shown that SB 11285 is effective in tumor growth inhibition in multiple pre-clinical models of cancer. Spring Bank recently announced that its Investigational New Drug application for a Phase 1 trial of IV SB 11285 was cleared by The U.S. Food and Drug Administration for clinical testing, and Spring Bank anticipates that a Phase 1 trial for IV SB 11285 will begin shortly.